TY - JOUR
T1 - Management of Platelet-Directed Pharmacotherapy in Patients With Atherosclerotic Coronary Artery Disease Undergoing Elective Endoscopic Gastrointestinal Procedures
AU - Becker, Richard C.
AU - Scheiman, James
AU - Dauerman, Harold L.
AU - Spencer, Frederick
AU - Rao, Sunil
AU - Sabatine, Marc
AU - Johnson, David A.
AU - Chan, Frances
AU - Abraham, Neena S.
AU - Quigley, Eamonn Martin
N1 - Funding Information:
Dr. Scheiman is a consultant for AstraZeneca, Novartis, Pfizer, Bayer, Takeda, Pozen, and NiCox, and has received speaker's honoraria from Takeda and AstraZeneca. Dr. Dauerman has received research grants and/or consulting fees from Abbott Vascular, Boston Scientific, Medtronic, The Medicines Company, and Bristol-Myers Squibb. Dr. Spencer is on the advisory board of GRACE (Global Registry of Acute Coronary Events), which is funded by Sanofi-Aventis; is on the Drug Safety Monitoring Board for Apixiban CAD studies, which is funded by Sanofi-Aventis; and is on the Drug Safety Monitoring Board for E5555 201 and 202 CAD studies, which is funded by EISAI. Dr. Rao is a consultant for and/or received honoraria from Sanofi-Aventis, Bristol-Myers Squibb, The Medicines Company, AstraZeneca, and received research funding from Momenta, Portola, and Cardis. Dr. Sabatine received research grant support and served on the advisory board for AstraZeneca; has received honoraria for education presentations and served on the Speaker's Bureau for Bristol-Myers Squibb; has received honoraria for educational presentations from Eli Lilly; has received research grant support, served on the scientific advisory boards, and received honoraria for education presentations from Sanofi-Aventis; and received research grant support from Schering-Plough. Dr. Johnson has received consulting fees/honoraria and research grant support from AstraZeneca, Novartis Pharmaceuticals Corp., and TAP Pharmaceuticals, and is on the Speakers' Bureau of AstraZeneca. Dr. Chan is the Chairman of the Steering Committee of the CONDOR study, which is a Pfizer-sponsored multicenter trial; receives consulting fees from Pfizer, Otsuka, and Takeda; received speaker's honoraria from Pfizer, AstraZeneca, and Takeda; and has received an investigator-initiated independent research grant from Pfizer.
PY - 2009/12/8
Y1 - 2009/12/8
N2 - The periprocedural management of patients with atherosclerotic coronary heart disease, including those who have heart disease and those who are undergoing percutaneous coronary intervention and stent placement who might require temporary interruption of platelet-directed pharmacotherapy for the purpose of an elective endoscopic gastrointestinal procedure, is a common clinical scenario in daily practice. Herein, we summarize the available information that can be employed for making management decisions and provide general guidance for risk assessment.
AB - The periprocedural management of patients with atherosclerotic coronary heart disease, including those who have heart disease and those who are undergoing percutaneous coronary intervention and stent placement who might require temporary interruption of platelet-directed pharmacotherapy for the purpose of an elective endoscopic gastrointestinal procedure, is a common clinical scenario in daily practice. Herein, we summarize the available information that can be employed for making management decisions and provide general guidance for risk assessment.
KW - coronary heart disease
KW - periprocedural risk assessment
KW - platelet antagonists
UR - http://www.scopus.com/inward/record.url?scp=70649088108&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=70649088108&partnerID=8YFLogxK
U2 - 10.1016/j.jacc.2009.09.012
DO - 10.1016/j.jacc.2009.09.012
M3 - Review article
C2 - 19942393
AN - SCOPUS:70649088108
VL - 54
SP - 2261
EP - 2276
JO - Journal of the American College of Cardiology.
JF - Journal of the American College of Cardiology.
SN - 0735-1097
IS - 24
ER -